AU2021301244A1 - Anti-S100A4 antibodies for the treatment of systemic sclerosis - Google Patents

Anti-S100A4 antibodies for the treatment of systemic sclerosis Download PDF

Info

Publication number
AU2021301244A1
AU2021301244A1 AU2021301244A AU2021301244A AU2021301244A1 AU 2021301244 A1 AU2021301244 A1 AU 2021301244A1 AU 2021301244 A AU2021301244 A AU 2021301244A AU 2021301244 A AU2021301244 A AU 2021301244A AU 2021301244 A1 AU2021301244 A1 AU 2021301244A1
Authority
AU
Australia
Prior art keywords
antibody
seq
use according
cdr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021301244A
Other languages
English (en)
Inventor
Tim Buss
Jörg Hans Wilhelm DISTLER
Jonas HALLÉN
Rizwan Iqbal HUSSAIN
Jörg KLINGELHÖFER
Darragh MACCANN
Michal TOMCIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calluna Pharma Inc
Original Assignee
Arxx Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arxx Therapeutics AS filed Critical Arxx Therapeutics AS
Publication of AU2021301244A1 publication Critical patent/AU2021301244A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021301244A 2020-06-30 2021-06-30 Anti-S100A4 antibodies for the treatment of systemic sclerosis Pending AU2021301244A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20183251.6 2020-06-30
EP20183251 2020-06-30
US202163147485P 2021-02-09 2021-02-09
US63/147,485 2021-02-09
PCT/EP2021/068038 WO2022003042A1 (en) 2020-06-30 2021-06-30 Anti-s100a4 antibodies for the treatment of systemic sclerosis

Publications (1)

Publication Number Publication Date
AU2021301244A1 true AU2021301244A1 (en) 2023-03-02

Family

ID=76601225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021301244A Pending AU2021301244A1 (en) 2020-06-30 2021-06-30 Anti-S100A4 antibodies for the treatment of systemic sclerosis

Country Status (7)

Country Link
US (1) US20230220058A1 (https=)
EP (1) EP4171752A1 (https=)
JP (1) JP2023531230A (https=)
CN (1) CN115867355A (https=)
AU (1) AU2021301244A1 (https=)
CA (1) CA3183062A1 (https=)
WO (1) WO2022003042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250011405A1 (en) * 2021-11-19 2025-01-09 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用
WO2025188905A1 (en) * 2024-03-08 2025-09-12 The Board Of Regents Of The University Of Texas System Anti-s100a antibodies and related compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201290B (zh) * 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
CA3207703A1 (en) * 2021-02-09 2022-08-18 Jonas Hallen Anti-s100a4 humanized antibodies, uses and methods

Also Published As

Publication number Publication date
JP2023531230A (ja) 2023-07-21
WO2022003042A1 (en) 2022-01-06
CN115867355A (zh) 2023-03-28
CA3183062A1 (en) 2022-01-06
EP4171752A1 (en) 2023-05-03
US20230220058A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
AU2018266784C9 (en) LRRC33 inhibitors and use thereof
KR101800467B1 (ko) 루푸스 치료 방법 및 조성물
US20230220058A1 (en) Anti-S100A4 antibodies for the treatment of systemic sclerosis
AU2016229810A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
KR20130100918A (ko) Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능
JP2022535062A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
KR20250005246A (ko) 항-cd19 작용제에 대한 투여 요법 및 이의 용도
JP2025016653A (ja) Ｍｕｓｋ阻害
NL2021591B1 (en) MuSK activation
US20240043562A1 (en) Musk activation
NL2021589B1 (en) MuSK inhibition
CA3099260C (en) Lrrc33 inhibitors and use thereof
HK40103766A (en) Lrrc33 inhibitors and use thereof